Cancer Immunology Reserch

A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

by

Cancer Immunol Res. 2024 Sep 30. doi: 10.1158/2326-6066.CIR-23-1027. Online ahead of print. ABSTRACT Ovarian cancers and microsatellite stable (MSS) colorectal cancers (CRC) are insensitive to anti-PD1 immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggests a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase 1 dose-escalation study of pembrolizumab … Read more

Deleting Trim33 in myeloid cells improves the efficiency of radiotherapy through an interferon beta dependent anti-tumor immune response

by

Cancer Immunol Res. 2024 Sep 26. doi: 10.1158/2326-6066.CIR-24-0026. Online ahead of print. ABSTRACT Radiotherapy (RT) triggers an immune response that contributes to anti-tumor effects. Induction of interferon beta (IFN-β) is a key event in this immunogenicity of RT. We have previously shown that TRIM33, a chromatin reader, restrains IFN-β expression in Toll-like receptor-activated myeloid cells. … Read more

Hyper-Interferon Sensitive influenza induces adaptive immune responses and overcomes resistance to anti-PD-1 in murine non-small cell lung cancer

by

Cancer Immunol Res. 2024 Sep 26. doi: 10.1158/2326-6066.CIR-23-1075. Online ahead of print. ABSTRACT Despite recent advances in immunotherapy with immune checkpoint inhibitors (ICI), many patients with non-small cell lung cancer (NSCLC) fail to respond or develop resistance after an initial response. In situ vaccination (ISV) with engineered viruses has emerged as a promising antigen-agnostic strategy … Read more

Targeting BTN2A1 enhances Vγ9Vδ2 T-cell effector functions and triggers tumor cell pyroptosis

by

Cancer Immunol Res. 2024 Sep 20. doi: 10.1158/2326-6066.CIR-23-0868. Online ahead of print. ABSTRACT Vγ9Vδ2 T cells are potent but elusive cytotoxic effectors. Butyrophilin subfamily 2 member A1 (BTN2A1) is a surface protein that has recently been shown to bind the Vγ9 chain of the γδ T-cell receptor (TCR) but its precise role in modulating Vγ9Vδ2 … Read more

Peripheral blood-derived PD-1/CD28-CD19-CAR-modified PD-1+ T-cell therapy in patients with solid tumors

by

Cancer Immunol Res. 2024 Sep 16. doi: 10.1158/2326-6066.CIR-24-0037. Online ahead of print. ABSTRACT T cells expressing PD-1 in the peripheral blood (PB) of patients with tumors possess therapeutic potential; however, the immunosuppressive, PD1-triggered signaling pathway and limited proliferative capacity of PD-1+ T cells present challenges to their therapeutic application. Here, we observed no discernible distinction … Read more

The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer

by

Cancer Immunol Res. 2024 Sep 13:OF1-OF9. doi: 10.1158/2326-6066.CIR-23-0642. Online ahead of print. ABSTRACT Neutrophils are the primary myeloid cells that are recruited to inflamed tissues, and they are key players during colitis, being also present within the tumor microenvironment during the initiation and growth of colon cancer. Neutrophils fundamentally serve to protect the host against … Read more

Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment

by

Cancer Immunol Res. 2024 Sep 13. doi: 10.1158/2326-6066.CIR-24-0469. Online ahead of print. ABSTRACT Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely associated with tobacco-associated lung adenocarcinoma (LUAD) in a human-relevant mouse model. Furthermore, we demonstrated that the … Read more

PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma

by

Cancer Immunol Res. 2024 Sep 13. doi: 10.1158/2326-6066.CIR-23-1094. Online ahead of print. ABSTRACT The great success of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with B-cell malignancies has prompted its translation to solid tumors. In the case of glioblastoma (GBM), clinical trials have shown modest efficacy, but efforts to develop more … Read more

CD91 and its ligand gp96 confer cross-priming capabilities to multiple APCs during immune responses to nascent, emerging tumors

by

Cancer Immunol Res. 2024 Sep 13. doi: 10.1158/2326-6066.CIR-24-0326. Online ahead of print. ABSTRACT During cancer immunosurveillance, dendritic cells (DCs) play a central role in orchestrating T-cell responses against emerging tumors. Capture of miniscule amounts of antigen along with tumor-initiated costimulatory signals can drive maturation of DCs. Expression of CD91 on DCs is essential in cross-priming … Read more

Integrated germline and somatic features reveal divergent immune pathways driving response to immune checkpoint blockade

by

Cancer Immunol Res. 2024 Sep 10. doi: 10.1158/2326-6066.CIR-24-0164. Online ahead of print. ABSTRACT Immune Checkpoint Blockade (ICB) has revolutionized cancer treatment, however the mechanisms determining patient response remain poorly understood. Here, we used machine learning to predict ICB response from germline and somatic biomarkers and interpreted the learned model to uncover putative mechanisms driving superior … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri